關鍵數據
164.570今開
168.360最高
1.31M成交量
38.36本益比TTM
20.27本益比動
--股利TTM
1.90%換手率
165.680昨收
162.425最低
156.84M成交額
27.38本益比靜
8.79市淨率
0.00%股息率 TTM
9.31%ROA
354.88052週最高
1.11量比
418.30M淨利潤
69.26M總股本
4.3105每股盈餘TTM
1.14Beta
23.00%ROE
140.63052週最低
3.58%振幅
69.45%毛利率
11.45B總市值
0.34回報/風險
2.14%風險率
操作建議
Insulet Corp當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名14/199位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為243.88。中期看,股價處於平穩狀態。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。
壓力支撐

由於公司未披露,未能獲取相關數據
Insulet Corp新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Zimmer Biomet Holdings Inc
ZBH
31
技術指標
財務指標
每股收益

由於公司未披露,未能獲取相關數據
營業總收入

由於公司未披露,未能獲取相關數據
Insulet Corp簡介
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
公司代碼PODD
公司Insulet Corp
CEOMcevoy (Ashley)
網址https://www.omnipod.com
公司股東
常見問題
Insulet Corp(PODD)的當前股價是多少?
Insulet Corp(PODD)的當前股價是 165.35。
Insulet Corp股票的52週最高點是多少?
Insulet Corp股票的52週最高點是354.88。
Insulet Corp股票的52週最低點是多少?
Insulet Corp股票的52週最低點是140.63。
現在Insulet Corp(PODD)的股票是買入、持有還是賣出?
根據分析師評級,Insulet Corp(PODD)的總體評級為買入,目標價格為243.88。
Insulet Corp(PODD)股票的每股收益(EPS TTM)是多少
Insulet Corp(PODD)股票的每股收益(EPS TTM)是3.51。